Using this approach, they confirmed the potential of anti‐major histocompatibility complex (MHC) class I chain‐related protein A (MICA)and MHC class I chain‐related protein B (MICB) as an antitumor therapeutic agent by disrupting the NKG2D‐MICA/B pathway, consequently enhancing NK cell infiltration and immune activation toward the tumor. The gene discussed is MICA; the disease is neoplasm.